DURAGESIC-100
LOE ApproachingNDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Aug 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DURAGESIC-100 is a transdermal extended-release fentanyl patch indicated for chronic pain management in opioid-tolerant patients. As a potent synthetic opioid delivered through a film formulation, it provides sustained analgesia over an extended dosing interval. The exact indication profile is not publicly detailed in available data.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), signaling potential team restructuring and shift toward maintenance or LOE-mitigation strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DURAGESIC-100 represents a legacy asset with minimal new career openings (0 linked jobs), reflecting its mature lifecycle stage. Working on this product offers stability and deep disease/market knowledge but limited growth trajectory or innovation exposure.
Brand ManagerProduct Manager
Worked on DURAGESIC-100 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.